Clinical Trial Results:
Comparative Prospective Randomized Study in Postoperative Cardiac Surgery Patients on Analgesia with Morphine Continuous Infusion or Sublingual Sufentanil (Zalviso®).
Summary
|
|
EudraCT number |
2017-004038-28 |
Trial protocol |
BE |
Global end of trial date |
06 Aug 2024
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
09 May 2025
|
First version publication date |
09 May 2025
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
Zalviso
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
UZ Brussel
|
||
Sponsor organisation address |
Laarbeeklaan, Brussel, Belgium,
|
||
Public contact |
Virgini Van Buggenhout, Universitair Ziekenhuis Brussel, +32 24776001, virgini.vanbuggenhout@uzbrussel.be
|
||
Scientific contact |
Virgini Van Buggenhout, Universitair Ziekenhuis Brussel, +32 24776001, virgini.vanbuggenhout@uzbrussel.be
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
30 Dec 2019
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
06 Aug 2024
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The present study aims to assess postoperative pain after cardiac surgery by means of a standardized scoring system.
|
||
Protection of trial subjects |
Patients were followed up during the entire study after informed consent was given. This to assess safety of the IMP used.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
15 Nov 2017
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 80
|
||
Worldwide total number of subjects |
80
|
||
EEA total number of subjects |
80
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
59
|
||
From 65 to 84 years |
21
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||
Recruitment details |
- | ||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||
Screening details |
- | ||||||||||||||||||||||||
Pre-assignment period milestones
|
|||||||||||||||||||||||||
Number of subjects started |
483 [1] | ||||||||||||||||||||||||
Number of subjects completed |
80 | ||||||||||||||||||||||||
Pre-assignment subject non-completion reasons
|
|||||||||||||||||||||||||
Reason: Number of subjects |
not meeting in- and exclusion criteria: 310 | ||||||||||||||||||||||||
Reason: Number of subjects |
not willing to give consent: 93 | ||||||||||||||||||||||||
Notes [1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: 483 patients were scheduled for cardiac surgery between june 2018 and september 2019. However only 80 were eligible of those 483 patients. |
|||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||
Period 1 title |
study conduct (overall period)
|
||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
sublingual sufentanil tablet system | ||||||||||||||||||||||||
Arm description |
- | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
sufentanil
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||
Routes of administration |
Sublingual use
|
||||||||||||||||||||||||
Dosage and administration details |
15-microgram sublingual sufentanil tablet with a 20-minute lag time between each dose
|
||||||||||||||||||||||||
Arm title
|
continuous morphine pump | ||||||||||||||||||||||||
Arm description |
- | ||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||
Investigational medicinal product name |
morphine
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||
Dosage and administration details |
continuous mrophine pump: 0.1 mg/kg/dose
|
||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
sublingual sufentanil tablet system
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
continuous morphine pump
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
sublingual sufentanil tablet system
|
||
Reporting group description |
- | ||
Reporting group title |
continuous morphine pump
|
||
Reporting group description |
- |
|
|||||||||||||
End point title |
cumulative pain score 24hrs after extubation | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
24hrs after extubation
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square test | ||||||||||||
Comparison groups |
continuous morphine pump v sublingual sufentanil tablet system
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
cumulative pain score 48hrs after extubation | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
pain score 48 hours after extubation
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
cumulative pain score 63 hrs after extubation | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
pain score 63 hours after extubation
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
pain score hour 4 | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
pain score on hour 4 between extubation and discharge of ICU
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
pain score hour 11 | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
pain score 11 hours after extubation and still in ICU
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
pain score hour 12 | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
pain score 12 hours after extubation and patient still on ICU
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
pain score hour 16 | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
pain score 16 hours after extubation and still on ICU
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
pain score hour 20 | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
pain score 20 hrs after extubation and still on ICU
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
pain score hour 46 | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
pain score 46 hours after extubation and still on ICU ward
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
pain score hour 17 | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
pain score 17 hours after extubation and still on ICU ward
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
RASS POD 1 20:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Richmond agitation-sedation scale post operative day 1 20:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
cumulative opioid dose | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
in milligrams intravenous morphine equivalents
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
continuous morphine pump v sublingual sufentanil tablet system
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
||||||||||
End point title |
Incidence of PONV | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
incindence of postoperative nausea and vomiting during study conduct
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
incidence of sedation | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
incidence of sedation during study conduct
|
|||||||||
|
||||||||||
Statistical analysis title |
chi square | |||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
|||||||||
Number of subjects included in analysis |
64
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
equivalence | |||||||||
P-value |
< 0.05 | |||||||||
Method |
Chi-squared | |||||||||
Confidence interval |
|
|||||||||||||
End point title |
RASS POD 1 8:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Richmond agitation-sedation scale post operative day 1 8:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
continuous morphine pump v sublingual sufentanil tablet system
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
RASS POD 2 8:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Richmond agitation-sedation scale post operative day 2 8:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
RASS POD 2 20:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Richmond agitation-sedation scale post operative day 2 20:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
RASS POD 3 8:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Richmond agitation-sedation scale post operative day 3 8:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
RASS POD3 20:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Richmond agitation-sedation scale post operative day 3 20:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
RR POD1 8:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
mean respiratory rate post operative day 1 8:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
RR POD 1 20:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Respiratory rate post operative day 1 20:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
continuous morphine pump v sublingual sufentanil tablet system
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
RR POD 2 8:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Respiratory rate post operative day 2 8:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
RR POD 3 8:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Respiratory rate post operative day 3 8:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
RR POD 3 20:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Respiratory rate post operative day 3 20:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
RR POD 2 20:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
respiratory rate post operative day 2 20:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
continuous morphine pump v sublingual sufentanil tablet system
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
HR POD 1 8:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
heart rate post operative day 1 8:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
HR POD 1 20:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
heart rate postoperative day 1 20:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
HR POD 2 8:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
heart rate postoperative day 2 8:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
HR POD 2 20:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
heart rate postoperative day 2 20:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
HR POD 3 8:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
heart rate postoperative day 3 8:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
HR POD 3 20:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
heart rate postoperative day 3 20:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
BP POD 1 8:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
blood pressure post operative day 1 8:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
BP POD 1 20:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
blood pressure post operative day 1 20:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
BP POD 2 8:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
blood pressure post operative day 2 8:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
BP POD 2 20:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
blood pressure post operative day 2 20:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
BP POD 3 8:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
blood pressure post operative day 3 8:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
BP POD 3 20:00 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
blood pressure post operative day 3 20:00
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
chi square | ||||||||||||
Comparison groups |
sublingual sufentanil tablet system v continuous morphine pump
|
||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Confidence interval |
|
|||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
adverse events were assessed as from signing the ICF till post operative day 3 (end of study).
|
||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||
Dictionary version |
22
|
||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||
Reporting group title |
subject group
|
||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |